<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0703245036
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REXULTI 3 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BREXPIPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        405.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Otsuka Pharmaceutical Co., Ltd." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Otsuka Pharmaceutical Co., Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">REXULTI tablets contain the active substance brexpiprazole.</p><p style="text-align:justify">REXULTI is a prescription medicine used to treat adults aged 18 and older who suffer from:</p><ul><li style="text-align:justify">Major depressive disorder (MDD): REXULTI is used in addition to your antidepressant medicine, when your doctor determines that the antidepressant alone did not adequately treat your depression.</li><li style="text-align:justify">Schizophrenia: REXULTI is used to treat symptoms of schizophrenia. Your doctor may continue to prescribe REXULTI even when you are feeling better in order to prevent the re-emergence of symptoms.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>Do not take REXULTI:</strong><br />if you are allergic to brexpiprazole or any of the other ingredients of this medicine (listed in section 6).</p><p style="text-align:justify"><strong>Warnings and precautions</strong><br />Before taking REXULTI, tell your doctor if you:</p><ul><li style="text-align:justify">are an elderly person with dementia (loss of memory and other mental abilities);</li><li style="text-align:justify">have diabetes or high blood sugar or a family history of diabetes or high blood sugar;</li><li style="text-align:justify">have high levels of cholesterol, triglycerides, LDL-cholesterol, or low levels of HDL cholesterol;</li><li style="text-align:justify">have or had seizures (convulsions);</li><li style="text-align:justify">have or had low or high blood pressure;</li><li style="text-align:justify">have or had heart problems or a stroke;</li><li style="text-align:justify">have or had a low white blood cell count;</li><li style="text-align:justify">have liver or kidney problems;</li></ul><p style="text-align:justify">While taking REXULTI:</p><ul><li style="text-align:justify">tell your doctor if you have any of these symptoms of high blood sugar: feel very thirsty, feel sick to your stomach, need to urinate more than usual, feel very hungry, feel weak or tired, feel confused, or your breath smells fruity;</li><li style="text-align:justify">tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever, sweating, altered mental status, or very rapid or irregular heart beat;</li><li style="text-align:justify">tell your doctor immediately it you experience involuntary, irregular muscle movements, especially in the face, such as tongue and lips;</li><li style="text-align:justify">tell your doctor immediately if you are having any thoughts or feelings about harming yourself. Suicidal thoughts and behavior have been reported during antipsychotic treatment;</li><li style="text-align:justify">avoid getting over-heated or dehydrated. Do not over-exercise and drink plenty of water.</li><li style="text-align:justify">tell your doctor immediately if you have problems with impulse control (i.e. urge to gamble, spend money, eat or other urges or sex addiction).</li><li style="text-align:justify">tell your doctor immediately if you have or had a low number of white blood cells in your blood and get a fever or any other sign of infection. This may for example be the case if other medicines lowered your white blood cells in the past. Your doctor will regularly measure the white blood cells in your blood to minimise the risk for diseases called leukopenia, neutropenia and agranulocytosis. It is important that you get your blood checked regularly as this may be fatal. Your doctor will stop the treatment immediately if the white blood cells in your blood are too low.</li></ul><p style="text-align:justify"><strong>Children and adolescents</strong><br />Do not use this medicine in children and adolescents under 18 years of age. The safety and effectiveness in these patients was not evaluated.</p><p style="text-align:justify"><strong>Other medicines and REXULTI</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. Your doctor can tell you if it is safe to take REXULTI with your other medicines. Do not start or stop any medicines while taking REXULTI without talking to your doctor first.</p><p style="text-align:justify">Taking REXULTI tablets with other medicines may require to change your dose of REXULTI tablets. It is especially important to mention to your doctor if you take any of the following:</p><ul><li style="text-align:justify">Blood pressure-lowering medicines,</li><li style="text-align:justify">Medicines to correct heart rhythm (e.g. quinidine),</li><li style="text-align:justify">Antidepressants (e.g. paroxetine, fluoxetine) or herbal remedy for depression (e.g. St John&rsquo;s Wort),</li><li style="text-align:justify">Medicines to treat fungal infections (e.g. ketoconazole),</li><li style="text-align:justify">Antibiotic medicines (e.g. rifampicin, clarithromycin),</li><li style="text-align:justify">Certain medicines to treat HIV infection (e.g. ritonavir).</li><li style="text-align:justify">Medicines to treat epilepsy (e.g. carbamazepine)</li></ul><p style="text-align:justify">These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with REXULTI tablets, you should see your doctor.</p><p style="text-align:justify"><strong>REXULTI with food and alcohol</strong><br />REXULTI can be taken regardless of meals.<br />Alcohol should be avoided.</p><p style="text-align:justify"><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p style="text-align:justify">The effect of REXULTI on your unborn baby is not known. Using REXULTI in the last trimester of pregnancy may cause muscle movement problems, medicine withdrawal symptoms, or both of these in your newborn.</p><p style="text-align:justify">It is not known if brexpiprazole passes into breast milk. You and your doctor should decide if you will take REXULTI during breastfeeding.</p><p style="text-align:justify"><strong>Driving and using machines</strong><br />Do not drive a car, operate machinery, or do other dangerous activities until you know how REXULTI affects you. REXULTI may make you feel drowsy.</p><p style="text-align:justify"><strong>REXULTI tablets contain lactose</strong><br />If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p style="text-align:justify"><strong>Major Depressive Disorder:</strong><br />The recommended dose in Major Depressive Disorder is 2 mg once daily. In order to reduce the risk of side effects the dose is increased gradually to reach the recommended dose.</p><p style="text-align:justify">The usual starting dose is 0.5 mg or 1 mg once daily for the first week, which is then increased gradually up to the target recommended dose of 2 mg. The maximum recommended daily dosage is 3 mg.</p><p style="text-align:justify"><strong>Schizophrenia</strong><br />The recommended dose in Schizophrenia is 2-4 mg once daily. In order to reduce the risk of side effects the dose is increased gradually to reach the recommended dose.</p><p style="text-align:justify">The usual starting dose is 1 mg once daily for the first 4 days. This is increased to 2 mg from Day 5 through 7. From Day 8 the dose may be increased up to 4 mg once a day. The maximum recommended daily dosage is 4 mg.</p><p style="text-align:justify">The recommended dose for the continuation of treatment to prevent re-emergence of symptoms is 2-4 mg once daily.</p><p style="text-align:justify">Your doctor will advise on the best dose for you.</p><p style="text-align:justify">Try to take your REXULTI tablets at the same time each day. Swallow your tablets whole with water. Do not split, chew, or crush the tablets.</p><p style="text-align:justify"><strong>If you take more REXULTI than you should</strong><br />If you have taken too many REXULTI tablets, contact your doctor right away even if there are no symptoms. If you cannot reach your doctor, go to the nearest hospital and take the pack with you.</p><p style="text-align:justify"><strong>If you forget to take REXULTI</strong><br />Take the missed dose as soon as you remember. If you are close to your next dose, just skip the missed dose and take your next dose at your regular time. Do not take a double dose to make up for a forgotten dose.</p><p style="text-align:justify"><strong>If you stop taking REXULTI</strong><br />If you stop taking REXULTI you may experience re-emergence of your symptoms. It is not recommended to stop taking REXULTI without prior consultation with your doctor.</p><p style="text-align:justify">If you have any further questions on the use of REXULTI, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="text-align:justify"><strong>Common (may affect up to 1 in 10 people):</strong><br />Increased appetite, restlessness, insomnia, anxiety, inner restlessness, tremor, sedation extrapyramidal disorder (involuntory movments, slow and impaired voluntory movements, and changes in muscle tone), dizziness, somnolence, vision blurred (blurry vision), high blood pressure, diarrhoea, dry mouth, stomach pain , constipation,, rash , back pain, pain in arms and/or legs, fatigue, pain weight increased, increased blood prolactin (increased levels of hormone called &ldquo;prolactin&rdquo;), decreased blood cortisol (decreased levels of hormone called &ldquo;cortisol&rdquo;), Creatinine Phosphokinase Increased (increase in enzyme important for muscle function).muscle strain.</p><p style="text-align:justify"><strong>Uncommon (may affect up to 1 in 100 people):</strong><br />Tension, parkinsonism (tremor, stiffness and shuffling), cough, tinnitus, palpitations (feeling your heartbeat) flatulence, salivary hypersecretion, night sweats, muscle pain.</p><p style="text-align:justify"><strong>Other side effect may also occur with low frequency:</strong><br />Indigestion, agitation and hypersensitivity.Some people taking Rexulti have had unusual urges, such as gambling, eating that you cannot control (compulsive), compulsive shopping and other compulsive behaviours. If you or your family members notice that you are having unusual urges or behaviours, talk to your doctor Rexulti may cause serious side effects, including:</p><ul><li style="text-align:justify">Increased risk of death in elderly people with dementia-related psychosis. Medicines like REXULTI can raise the risk of death in elderly who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). REXULTI is not approved for the treatment of patients with dementiarelated psychosis.</li><li style="text-align:justify">Risk of suicidal thoughts or actions. Antidepressant medicines, depression and other serious mental illnesses, may cause suicidal thoughts or actions. REXULTI is not approved for the treatment of people younger than 18 years of age.<ul><li>Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment.</li><li>Depression and other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manicdepressive illness) or suicidal thoughts or actions.</li><li>How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?<ul><li>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</li><li>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</li><li>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.</li></ul></li></ul></li></ul><p style="text-align:justify">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:</p><ul><li style="text-align:justify">thoughts about suicide or dying</li><li style="text-align:justify">new or worsening depression</li><li style="text-align:justify">feeling very agitated or restless</li><li style="text-align:justify">panic attacks</li><li style="text-align:justify">new or worsening irritability</li><li style="text-align:justify">an extreme increase in activity or talking (mania)</li><li style="text-align:justify">attempts to commit suicide</li><li style="text-align:justify">new or worsening anxiety</li><li style="text-align:justify">acting on dangerous impulses</li><li style="text-align:justify">trouble sleeping (insomnia)</li><li style="text-align:justify">acting aggressive, being angry, or violent</li><li style="text-align:justify">other unusual changes in behavior or mood&rdquo;</li></ul><p style="text-align:justify">These are not all the possible side effects of REXULTI. For more information, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP. The expiry date refers to the last day of that month.</p><p style="text-align:justify">Store REXULTI at room temperature, below 30&deg;C.</p><p style="text-align:justify">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is brexpiprazole. Each tablet contains 0.25 mg/ 0.5 mg / 1mg / 2 mg / 3 mg / 4 mg of brexpiprazole</p><p>The other excipients are lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, titanium dioxide, iron oxide red (0.25 mg, 0.5 mg, 3 mg), iron oxide yellow (0.25 mg, 0.5 mg, 1 mg, 2 mg), ferrosoferric oxide (0.25 mg, 2 mg, 3mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                0.25 mg:    Round, shallow convex and bevel-edged, light brown, debossed with BRX and 0.25 one side
0.5 mg:    Round, shallow convex and bevel-edged, light orange, debossed with BRX and 0.5 one side
1 mg:    Round, shallow convex and bevel-edged, light yellow, debossed with BRX and 1 one side
2 mg:    Round, shallow convex and bevel-edged, light green, debossed with BRX and 2 one side
3 mg:    Round, shallow convex and bevel-edged, light purple, debossed with BRX and 3 one side
4 mg:    Round, shallow convex and bevel-edged, white, debossed with BRX and 4 one side
REXULTI tablets are supplied in blisters packed in cartons containing 28 tablets.
Not all strengths may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Aja Pharmaceutical Industries Co<br />Industrial City,<br />Hail,<br />Saudi Arabia</p><p><strong>Manufacturers</strong></p><p>H. Lundbeck A/S<br />Ottiliavej 9<br />2500 Valby<br />Denmark<br />Under License from Otsuka Pharmaceutical Co., Ltd</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:justify">تحتوي أقراص عقار ريكزولتي على المادة الفعَّالة بريكسبيبرازول.</p><p dir="RTL" style="text-align:justify">عقار ريكزولتي هو دواء وصفي يستخدم لعلاج البالغين من سن 18 عاًمًا فأكبر والذين يعانون من:&nbsp;</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; الاضطراب الاكتئابي الحاد: يُستَخَدَم عقار ريكزولتي بالإضافة إلى الدَّواء المضاد للاكتئاب الخاص بك، عندما يقرر طبيبك أنَّ استخدام مضاد الاكتئاب وحده لم يعالِج الاكتئاب لديك بشكل كافٍ.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; الُفُصام: يستخَدَم عقار ريكزولتي لعلاج أعراض الفُصام. قد يواصل طبيبك وصف عقار ريكزولتي حتى عندما تشعر بتحسن؛ في سبيل منع عودة ظهور الأعراض مرة أخرى.</p><p style="text-align:justify">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>لا تتناول عقار ريكزولتي في الحالة الآتية:</strong></p><p dir="RTL" style="text-align:justify">إذا كنت تعاني من حساسية تجاه بريكسبيبرازول أو أيٍّ من المكونات الأخرى لهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL" style="text-align:justify"><strong>تحذيرات واحتياطات </strong>&nbsp;&nbsp;</p><p dir="RTL" style="text-align:justify">قبل تناُوُل عقار ريكزولتي ، أخبر طبيبك إذا كنت تعاني من أي مما يلي:</p><ul><li dir="RTL" style="text-align:justify">إذا كنت من كبار السن وتعاني من الخرف (فقدان الذاكرة والقدرات العقلية&nbsp;الأخرى).</li><li dir="RTL" style="text-align:justify">إذا كنت تعاني من مرض السُّكَّرِي أو ارتفاع في مستوى سكر الدَّم أو تاريخ مرضي عائلي من الإصابة بمرض السُّكَّرِي أو ارتفاع سكر الدَّم.</li><li dir="RTL" style="text-align:justify">إذا كان لدیك ارتفاع في مستويات الكوليسترول، أو الدهون الثلاثية، أو كوليسترول البروتين الدهني منخفض الكثافة أو مستوى منخفض من كوليسترول البروتين الدهني مرتفع الكثافة.</li><li dir="RTL" style="text-align:justify">إذا كنت مصاًبًا أو أصُبت من قبل بنوبات تشنجية (اختلاجات.)</li><li dir="RTL" style="text-align:justify">إذا كنت تعاني أو قد عانيت من ضغط دم مرتفع أو منخفض.</li><li dir="RTL" style="text-align:justify">إذا كنت مصاًبًا أو أصبت من قبل بمشاكل بالقلب أو سكتة دماغية.</li><li dir="RTL" style="text-align:justify">إذا كنت تعاني أو قد عانيت من قلة عدد خلايا الدَّم البيضاء.</li><li dir="RTL" style="text-align:justify">إذا كنت تعاني من مشاكل بالكبد أو الُكُلى.</li></ul><p dir="RTL" style="text-align:justify">عند تناُوُل عقار ريكزولتي</p><ul><li dir="RTL" style="text-align:justify">أخبر طبيبك إذا كنت تعاني من أي من الأعراض التالية لارتفاع سكر الدَّم: الشعور بالعطش الشديد، اعياء بالمعدة، الحاجة إلى التَّبول أكثر من المعتاد، الشعور بجوع شديد، الشعور بضعف أو إجهاد ،الشعور بارتباك، أو تغير&nbsp;رائحة الفم لدیك إلى رائحة الفواكه.</li><li dir="RTL" style="text-align:justify">أخبر&nbsp;طبيبك فوًرًا إذا كنت تعاني من تصلب العضلات أو عدم المرونة مع حمى مرتفعة، أو تعرُّق، أو تغیر بالحالة الذهنية، أو إذا كانت ضربات القلب سريعة جدًّا أو غير&nbsp;منتظمة.</li><li dir="RTL" style="text-align:justify">أخبر طبيبك فوًرًا إذا كنت تعاني من حركات عضلية لاإرادية غير منتظمة، خاصًةً بالوجه، مثل: اللسان والشفتين.</li><li dir="RTL" style="text-align:justify">أخبر طبيبك فوًرًا إذا كان لديك أي أفكار أو شعور بالرَّغبة في إيذاء نفسك. تم الإبلاغ عن أفكار وسلوكيات انتحارية أثناء العلاج بمضادات الذهان.</li><li dir="RTL" style="text-align:justify">تجنب زيادة حرارة الجسم أو جفافه. لا تفرط في ممارسة التمارين الرياضية، وتناول كمية كبيرة من الماء.</li><li dir="RTL" style="text-align:justify">اخبر طبيبك على الفور إذا كنت تعاني من مشاكل في السيطره على الاندفاع (أي: هناك رغبة ملحة للمقامره وإنفاق المال وتناول الطعام أو رغبات ملحة أخرى أو إدمان ممارسة الجنس)</li><li dir="RTL" style="text-align:justify">أخبر طبيبك فورا إذا كنت تعاني أو قد عانيت من انخفاض في عدد خلايا الدم البيضاء لديك وإذا كنت تعاني من حمى أو أي علامة أخرى للإصابة بالعدوى. فقد يكون ذلك على سبيل المثال في حالة استخدام ادوية اخرى قد خفضت من تعداد خلايا الدم البيضاء لديك في الماضي. سيقيس طبيبك خلايا الدم البيضاء لديك بشكل منتظم للحد من خطر الإصابة بأمراض تدعى نقص كريات الدم البيضاء وقلة خلايا العدلات وندرة خلايا المحببات. من الهام أن يتم فحص دمك بشكل منتظم، لأن تلك الأمراض قد تؤدي إلى الوفاة. سيوقف طبيبك العلاج فورا في حال انخفاض خلايا الدم البيضاء لديك بشكل شديد.</li></ul><p dir="RTL" style="text-align:justify"><strong>الأطفال والمراهقون&nbsp; </strong></p><p dir="RTL" style="text-align:justify">لا تستخدم هذا الدَّواء مع الأطفال والمراهقين تحت سن 18 عاًمًا. لم يتم تقييم الأمان والفعالة في هؤلاء المرضى.</p><p dir="RTL" style="text-align:justify"><strong>تناُوُل عقار ريكزولتي&nbsp;مع أدوية أخرى</strong></p><p dir="RTL" style="text-align:justify">يرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخًرًا أو قد تتناول أية&nbsp;أدوية أخرى، بما في ذلك أية أدوية حصلت عليها دون وصفة طبية. قد يخبرك طبيبك إذا كان تناول عقار ريكزولتي&nbsp;مع أدوية أخرى أمًرًا آمًنًا أم لا. لا تبدأ في تناُوُل أي أدوية أو تتوقف عن تناولنا أثناء تناُوُل عقار ريكزولتي&nbsp;دون التَّحدث أوًلًا مع طبيبك.</p><p dir="RTL" style="text-align:justify">قد يتطلب تناُوُل أقراص عقار ريكزولتي&nbsp;مع الأدوية الأخرى تغيير جرعتك من أقراص عقار ريكزولتي&nbsp;. من المهم للغاية إخبار طبيبك إذا كنت تتناول أيا من الأدوية التالية:</p><p dir="RTL" style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية خافضة لضغط الدَّ م.</p><p dir="RTL" style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المعدِّلة للنظم القلبي (على سبيل المثال: كينيدين.)</p><p dir="RTL" style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب (على سبيل المثال: باروكسيتين&nbsp;وفلوكسيتين) أو العلاج بالأعشاب لعلاج الاكتئاب (على سبيل المثال: نبتة سانت جونز.)</p><p dir="RTL" style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج العدوى الفطرية (على سبيل المثال: كيتوكونازول.)</p><p dir="RTL" style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية المضادات الحيوية (على سبيل المثال: ِرِيفامبيسين&nbsp;وكلاريثروميسين.)</p><p dir="RTL" style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية معينة لعلاج عدوى فيروس نقص المناعة البشرية (على سبيل المثال: ريتونافير.)</p><p dir="RTL" style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج الصَّرع (على سبيل&nbsp;المثال: َكَرْباماِزبين.)</p><p dir="RTL" style="text-align:justify">قد تزيد هذه الأدوية من خطر حدوث الآثار الجانبية؛ إذا كان لديك أي أعراض غير عادية بعد تناُوُل أيٍّ من هذه الأدوية مع أقراص عقار ريكزولتي&nbsp;، يجب عليك مراجعة طبيبك.&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>تناُوُل عقار ريكزولتي&nbsp;مع الطعام والكحوليات</strong>&nbsp;</p><p dir="RTL" style="text-align:justify">يمكن تناُوُل عقار ريكزولتي&nbsp;بغض النَّظر عن الوجبات.</p><p dir="RTL" style="text-align:justify">يجب عليك تجنب تناُوُل الكحوليات.</p><p dir="RTL" style="text-align:justify"><strong>الحمل والرضاعة الطبيعية</strong>&nbsp;</p><p dir="RTL" style="text-align:justify">إذا كنِتِ حامًلًا أو مرضًعًا، أو تعتقدين أنِكِ حامل أو تخططين لذلك، فاستشيري طبيبك قبل تناُوُل هذا الدَّواء.</p><p dir="RTL" style="text-align:justify">من غير المعروف تأثير عقار ريكزولتي&nbsp;على الجنين. قد يسبب استخدام عقار ريكزولتي&nbsp;في الثلث الأخير من الحمل مشاكل في حركة العضلات، أو أعراض انسحابيه للدواء أو كلايهما في طفلِكِ حديث الولادة.&nbsp;</p><p dir="RTL" style="text-align:justify">من غير المعروف ما إذا كان بريكسبيبرازول يتسرب&nbsp;إلى لبن الأم أم لا. يجب أن تقرري أنِتِ وطبيبكِ ما إذا كنتِ ستتناولين عقار ريكزولتي&nbsp;أثناء الرضاعة الطبيعية أم لا.</p><p dir="RTL" style="text-align:justify"><strong>القيادة واستخدام الآلات</strong>&nbsp;</p><p dir="RTL" style="text-align:justify">تجنب قيادة السيارات أو تشغيل الآلات، أو القيام بأنشطة أخرى خطيرة حتى تعرف كيف يؤثر عقار ريكزولتي&nbsp;عليك. قد يشعرك عقار ريكزولتي&nbsp;بالنُّعاس.</p><p dir="RTL" style="text-align:justify"><strong>تحتوي أقراص عقار ريكزولتي&nbsp;على اللاكتوز.</strong></p><p dir="RTL" style="text-align:justify">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناُوُل هذا الدَّواء.&nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">تناول دائًمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. ُيرجى مراجعة طبيبك إذا لم تكن متأكًدًا من كيفية التَّناول.</p><p dir="RTL" style="text-align:justify"><u>الاضطراب الاكتئابي الحاد:</u>&nbsp;</p><p dir="RTL" style="text-align:justify">الجرعة الموصى بها في الاضطراب الاكتئابي الحاد هي 2 ملجم مرة واحدة يومياً. للحد من خطر حدوث الآثار الجانبية، يتم زيادة الجرعة تدريجياً حتى يتم الوصول إلى الجرعة الموصى بها.</p><p dir="RTL" style="text-align:justify">جرعة البدء الُمُعتادة هي 0.5 ملجم أو 1 ملجم مرة واحدة يومياً خلال الأسبوع الأول، ثم تتم زيادتها تدريجياً حتى الوصول للجرعة المستهدفة الُمُوصى بها وتبلغ 2 ملجم.</p><p dir="RTL" style="text-align:justify">الجرعة القصوى الموصى بها يومياً هي 3 ملجم.&nbsp;</p><p dir="RTL" style="text-align:justify"><u>الُفُصام:</u>&nbsp;</p><p dir="RTL" style="text-align:justify">الجرعة الموصى بها في حالات الُفُصُام هي من 2 - 4 ملجم مرة واحدة يومياً. للحد من خطر حدوث الآثار الجانبية، يتم زيادة الجرعة تدريجياً حتى يتم الوصول إلى الجرعة الموصى بها.&nbsp;</p><p dir="RTL" style="text-align:justify">تكون جرعة البدء المعتادة هي 1 ملجم مرة واحدة يومياً في الأربعة أيام الأولى. ثم تزيد الجرعة إلى 2 ملجم من اليوم الخامس إلى اليوم السابع. ومن اليوم الثامن قد تزداد الجرعة حتى 4 ملجم مرة واحدة يومياً.&nbsp;</p><p dir="RTL" style="text-align:justify">الجرعة القصوى الموصى بها يومياً ھي 4 ملجم.</p><p dir="RTL" style="text-align:justify">الجرعة الموصى بها لاستمرار العلاج لمنع عودة الأعراض هي 2-4 ملجم مرَّة واحدة يومياً.</p><p dir="RTL" style="text-align:justify">سيقوم طبيبك بنصحك بأفضل جرعة لك.</p><p dir="RTL" style="text-align:justify">حاول تناُوُل أقراص عقار ريكزولتي الخاصَّة بك في نفس الوقت كل يوم. ابتلع الأقراص كاملة مع الماء. لا تقم بكسر الأقراص أو مضغها أو طحنها.&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>إذا تناولت كمية أكثر مما يجب من عقار ريكزولتي</strong></p><p dir="RTL" style="text-align:justify">إذا كنت قد تناولت كمية من أقراص عقار ريكزولتي أكثر مما يجب، فاتصل بطبيبك فوًرًا حتى إذا لم تظهر عليك أي أعراض. إذا لم تتمكن من الوصول إلى طبيبك، قم بالذهاب إلى أقرب مستشفى وفي حوزتك العبوة.</p><p dir="RTL" style="text-align:justify"><strong>إذا أغفلت تناُوُل عقار ريكزولتي</strong></p><p dir="RTL" style="text-align:justify">فتناول الجرعة التي أغفلتها بمجرد تذكرها. إذا كان وقت الجرعة التالية قريبا جدًّا، فتجاوز الجرعة التي أغفلتها وتناول جرعتك التالية في وقتك المعتاد. لا تتناول جرعة مضاعفة لتعوض جرعة أغفلتها.&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>إذا توقفت عن تناُوُل عقار ريكزولتي </strong></p><p dir="RTL" style="text-align:justify">إذا توقفت عن تناُوُل عقار ريكزولتي، فقد تعاني من عودة الأعراض مرة أخرى. لا ينُصح بالتَّوقف عن تناُوُل عقار ريكزولتي دون استشارة مسبقة من طبيبك.</p><p dir="RTL" style="text-align:justify">إذا كانت لديك أية أسئلة إضافية حول استخدام عقار ريكزولتي، فاستشر طبيبك أو الصيدلي.&nbsp; &nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">مثله مثل كافة الأدوية، قد يسبب هذا الدَّواء آثاًرًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>شائعة (قد ُتُؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص:)</strong></p><p dir="RTL" style="text-align:justify">زيادة الشهية، تملل (شعور بعدم الارتياح)، أَرَق، قلق، تملل داخلي، ارتعاش، سكون، اضطراب النظام العصبي الحركي (حركات لاإرادية، بطء وقصور في الحركات الإرادية، وتغيرات في التناغم العضلي)، دوخة ،النعاس، عدم وضوح الرؤية، ارتفاع ضغط الدَّ م، إسهال، جفاف الفم، ألم بالمعدة، إمساك، طفح جلدي، ألم بالظهر ،ألم في الذراعين و/ أو الساقين، إرهاق، ألم، زيادة الوزن، ارتفاع مستوى البرولاكتين بالدَّم (ارتفاع مستويات هرمون يسمى &quot;برولاكتين&quot;)، انخفاض مستوى الكورتيزول (انخفاض مستويات هرمون يسمى &quot;كورتيزول&quot;)، زيادة ُفُسُفوكيناز الكرياتينين (زيادة في إنزيم ُمُهم للوظائف العضلية)، إجهاد العضلات.&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>غير شائعة (قد ُتُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص:)</strong></p><p dir="RTL" style="text-align:justify">توتر، الَبَارْكِنْسُوِنِية (ارتعاش عضلي وتصلب وجر القدمين)، سُعال، طنين بالأذن، خفقان (الشعور بضربات القلب)، انتفاخ البطن بالغازات، فرط إفراز اللعاب، تعرُّ ق ليلي، ألم عضلي.&nbsp; &nbsp;&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>قد تحدث أيضا آثار جانبية أخرى مع تكرارها بشكل منخفض:</strong></p><p dir="RTL" style="text-align:justify">عسر الهضم وِهياج وفرط الحساسية.&nbsp;</p><p dir="RTL" style="text-align:justify">بعض الأشخاص الذين يتناولون عقار ريكزولتي قد راودتهم رغبات ملحة غير معتادة مثل: المقامرة، تناول غير متحكم به للطعام (قهري)، تسوق قهري وغيره من السلوكيات القهرية. إذا لاحظت أو لاحظ أفراد عائلتك أنه تراودك رغبات ملحة أو سلوكيات غير معتادة، تحدث إلى طبيبك.</p><p dir="RTL" style="text-align:justify"><u>قد يسبب عقار ريكزولتي آثارًا جانبية خطيرة، بما في ذلك:</u></p><ul><li dir="RTL" style="text-align:justify">خطر متزايد لحدوث الوفاة في الأشخاص من كبار السن المصابين بالذهان المتعلق بالخرف. يمكن أن تزيد الأدوية مثل عقار ريكزولتي من خطر حدوث الوفاة في الأشخاص من كبار السن الذين فقدوا الصلة بالواقع (الذهان) وذلك بسبب التشوش وفقدان الذاكرة (الخَرَف). لم تتم التصديق على عقار ريكزولتي لعلاج المرضى المصابين بالذهان المتعلق بالخرف.</li><li dir="RTL" style="text-align:justify">خطر الأفعال أو الأفكار الانتحارية. قد تسبب الأدوية المُ ضادُّة للاكْتِئاب، الاكتئاب والأمراض العقلية الخطيرة الأخرى، القيام بأفعال انتحارية أو التفكير فيها. لم تتم التصديق على عقار ريكزولتي لعلاج اليافعين الذين تقل أعمارهم عن 18 عامًا</li><li dir="RTL" style="text-align:justify">قد تزيد الأدوية المُضادُّة للاكْتِئاب من الأفعال أو الأفكار الانتحارية لدى بعض الأطفال، المراهقين، أو صغار البالغين خلال الأشهر الأولى القليلة من العلاج.</li><li dir="RTL" style="text-align:justify">يعد الاكتئاب والأمراض العقلية الخطيرة الأخرى أهم أسباب الأفعال أو الأفكار الانتحارية. قد يكون بعض الأشخاص أكثر عرضة بشكل خاص لخطر الأفكار أو الأفعال الانتحارية. ويشمل ذلك الأشخاص المصابين (أو ممن لديهم تاريخ مرضي عائلي من الإصابة) بمرض ثنائي القطب (يدعى أيضًا المرض الاكتئابي الهوسي) أو بأفكار أو أفعال انتحارية.</li></ul><p dir="RTL" style="text-align:justify"><u>كيف يمكن مراقبة ومحاولة منع الأفعال والأفكار الانتحارية لديّ أو لدى أحد أفراد العائلة؟</u></p><ul><li dir="RTL" style="text-align:justify">أعر اهتمامًا كبيرًا لحدوث أي تغييرات، خاصَّة التغييرات المفاجئة، في المزاج أو السلوكيات أو الأفكار أو المشاعر. يعدّ ذلك مهمًّا للغاية عندما يتم بدء تناول أحد الأدوية المضادة للاكتئاب أو عند تغيير الجرعة.</li><li dir="RTL" style="text-align:justify">اتصل بمقدم الرعاية الصحية على الفور للإبلاغ عن حدوث أي تغييرات جديدة أو مفاجئة في المزاج أو السلوك أو الأفكار أو المشاعر.</li><li dir="RTL" style="text-align:justify">التزم بكل زيارات المتابعة مع مقدم الرعاية الصحية على النحو المقرر. اتصل بمقدم الرعاية الصحية بين الزيارات حسب الحاجة، خاصةً إذا راودتك مخاوف فيما يخص الأعراض.</li></ul><p dir="RTL" style="text-align:justify">اتصل بمقدم الرعاية الصحية فورًا إذا أُصبت أو إذا أُصيب أحد أفراد عائلتك بأي من الأعراض التَّالية، خاصةً إذا كانت جديدة أو إذا تفاقمت أو إذا كانت تثير قلقك:</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود أفكار متعلقة بالانتحار أو الموت.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب جديد أو متفاقم.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بهياج شديد أو تململ.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات هلع.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هياج جديد أو متفاقم.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة قصوى في النَّشاط أو الكلام (هوَس).</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محاولات انتحارية.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق جديد أو متفاقم.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصرف باندفاعات خطيرة.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في النوم (أَرَق).</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصرف بعدوانية أو غضب أو عنف.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات أخرى غير معتادة في السلوك أو المزاج.</p><p dir="RTL" style="text-align:justify">هذه ليست جميع الآثار الجانبية المحتملة لعقار ريكزولتي. لمزيد من المعلومات، يرجى استشارة طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL" style="text-align:justify">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك. يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">يحفظ هذا الدَّواء بعيدًا عن رؤية وُمُتناَوَل الأطفال.</p><p dir="RTL" style="text-align:justify">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على الشريط والعبوة الكرتونية بعد كلمة&quot; EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.&nbsp;</p><p dir="RTL" style="text-align:justify">يحَفَظ عقار ريكزولتي في درجة حرارة الغرفة، أقل من 30 درجة مئوية.&nbsp;</p><p dir="RTL" style="text-align:justify">لا تتخلص من أي أدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم َتَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة. ش</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">المادة الفعالة هي: بريكسبيبرازول. يحتوي كل قرص على 0.25 ملجم /0.5 ملجم /1 ملجم /2 ملجم/3 ملجم / 4ملجم من بريكسبيبرازول.</p><p dir="RTL" style="text-align:justify">المكونات الأخرى هي لاكتوز أحادي الهيدرات، نشاء الذرة، سليلوز دقيق التَّبلور، هيدروكسيبروبيل السليلوز، هيدروكسيبروبيل السليلوز منخفض الاستبدال، ستيرات الماغنسيوم، هيبروميلوز، تلك، ثاني أكسيد التيتانيوم، أكسيد الحديد الأحمر (0.25 ملجم ،0.50 ملجم، و3 ملجم)، أكسيد الحديد الأصفر (0.25 ملجم ،0.5 ملجم، 1 ملجم، و2 ملجم)، وأكسيد حديدوز الحديديك (0.25 ملجم، 2 ملجم، و3 ملجم.)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.25 ملجم: أقراص دائرية، محدبة مسطحة قليلا ذو حواف مشطوفه، بني فاتح، محفور على أحد جانبيها &quot;BRX&quot; و &quot;0.25&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 ملجم: أقراص دائرية، محدبة مسطحة قليلا ذو حواف مشطوفه، برتقالي فاتح، محفور على أحد جانبيها&nbsp;&quot;BRX&quot; و &quot;0.5&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 ملجم: أقراص دائرية، محدبة مسطحة قليلا ذو حواف مشطوفه، أصفر فاتح، محفور على أحد جانبيها&nbsp;&quot;BRX&quot; و &quot;1&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 ملجم: أقراص دائرية، محدبة مسطحة قليلا ذو حواف مشطوفه، أخضر فاتح، محفور على أحد جانبيها&nbsp;&quot;BRX&quot; و &quot;2&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 ملجم: أقراص دائرية، محدبة مسطحة قليلا ذو حواف مشطوفه، بنفسجي فاتح، محفور على أحد جانبيها&nbsp;&quot;BRX&quot; و &quot;3&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 ملجم: أقراص دائرية، محدبة مسطحة قليلا ذو حواف مشطوفه، أبيض، محفور على أحد جانبيها&nbsp;&quot;BRX&quot; و &quot;4&quot;</p><p dir="RTL">أقراص عقار ريكزولتي متاحة في شرائط داخل عبوات كرتونية محتوية على 28 قرًصًا.</p><p dir="RTL">قد لا يتم تسويق جميع التركيزات.&nbsp; &nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق</strong></p><p dir="RTL">شركة أجا للصناعات الدَّوائية</p><p dir="RTL">المدينة الصناعية،</p><p dir="RTL">مدينة حائل،</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">شركة إتش لوندبيك أيه/ إس</p><p dir="RTL">أوتيليافاي 9</p><p dir="RTL">2500 فالبي</p><p>الدانمارك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 11/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rexulti 0.25 mg, 0.5 mg,1 mg, 2 mg, 3 mg and 4 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg tablets contain 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg of brexpiprazole respectively
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                0.25mg: round, light brown
0.5mg: round light orange
1mg: round, light yellow
2mg: round, light green
3mg: round, light purple
4mg: round, white
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)</p><p>Treatment of schizophrenia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">For oral use once daily with or without food<br /><strong><u>Major Depressive Disorder</u></strong><br />The recommended starting dose for brexpiprazole as adjunctive treatment is 0.5 mg or 1 mg once daily.<br />Dose titration to 1 mg/day and up to the target dose of 2 mg/day should occur at intervals of up to 1 week based on the patient&rsquo;s clinical response and tolerability. The maximum recommended dose is 3mg/day. Periodically reassess to determine the continued need and appropriate dose for treatment.</p><p style="text-align:justify"><strong><u>Schizophrenia</u></strong><br />The recommended starting dose for brexpiprazole in the treatment of patients with schizophrenia is 1<br />mg once daily on days 1 to 4. The recommended target dose range is 2 mg to 4 mg once daily. Titrate to<br />2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient&rsquo;s clinical response<br />and tolerability. The maximum recommended daily dosage is 4 mg.</p><p style="text-align:justify"><u>Maintenance treatment:</u><br />The recommended maintenance dose range is 2 mg/day to 4 mg/day. Periodically reassess to<br />determine the continued need for maintenance treatment.</p><p style="text-align:justify"><u>Dosing Precautions</u><br /><em>Dosing Adjustment for Hepatic Impairment</em><br />For patients with moderate to severe hepatic impairment (Child-Pugh score &ge;7), the maximum<br />recommended dosage is 2 mg once daily for patients with MDD, and 3 mg once daily for patients with<br />schizophrenia.<br /><em>Dosing Adjustment for Renal Impairment</em><br />For patients with moderate, severe or end-stage renal impairment (creatinine clearance CLcr&lt;60<br />mL/minute), the maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg<br />once daily for patients with schizophrenia.</p><p style="text-align:justify"><strong>Dosing Modifications for CYP2D6 Poor Metabolizers and for Concomitant Use with CYP Inhibitors/Inducers</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="text-align:justify"><strong>Factors</strong></td><td style="text-align:justify"><strong>Adjusted Dosage</strong></td></tr><tr><td colspan="2" style="text-align:justify"><strong>CYP2D6 Poor Metabolizers</strong></td></tr><tr><td style="text-align:justify">Known CYP2D6 poor metabolizers</td><td style="text-align:justify">Administer half of the usual dose</td></tr><tr><td style="text-align:justify">Known CYP2D6 poor metabolizers<br />taking strong/moderate CYP3A4<br />inhibitors</td><td style="text-align:justify">Administer a quarter of the usual dose</td></tr><tr><td colspan="2" style="text-align:justify"><strong>Patients Taking CYP2D6 Inhibitors and/or CYP3A4 Inhibitors</strong></td></tr><tr><td style="text-align:justify">Strong CYP2D6 inhibitors*</td><td rowspan="2" colspan="1" style="text-align:justify">Administer half of the usual dose</td></tr><tr><td style="text-align:justify">Strong CYP3A4 inhibitors</td></tr><tr><td style="text-align:justify">Strong/moderate CYP2D6 inhibitors<br />with strong/moderate CYP3A4<br />inhibitors</td><td style="text-align:justify">Administer a quarter of the usual dose</td></tr><tr><td colspan="2" style="text-align:justify"><strong>Patients Taking CYP3A4 Inducers</strong></td></tr><tr><td style="text-align:justify">Strong CYP3A4 inducers**</td><td style="text-align:justify">Double usual dose over 1 to 2 weeks</td></tr></tbody></table><p style="text-align:justify">* REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6<br />inhibitors (e.g., paroxetine, fluoxetine).<br />** If the co-administered CYP3A4 inducer is discontinued, reduce the dosage to the original level over 1 to 2 weeks.a</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients. Reactions have included rash, facial
swelling, urticaria, and anaphylaxis.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Increased Mortality in Elderly Patients with Dementia-related Psychosis</u><br />Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo- treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.</p><p style="text-align:justify">Brexpiprazole is not approved for the treatment of dementia-related psychosis.</p><p style="text-align:justify"><u>Cerebrovascular Adverse Reactions</u><br />In placebo-controlled trials with some antipsychotic drugs in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated patients.</p><p style="text-align:justify"><u>Suicidal Risk</u><br />The possibility of a suicide attempt is inherent in psychotic illnesses, and major depressive disorder (MDD). Close supervision and appropriate clinical management of high-risk patients should accompany drug therapy.</p><p style="text-align:justify">In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in patients age 24 years and younger was greater in antidepressant-treated patients than in placebo-treated patients.</p><p style="text-align:justify">No suicides occurred in any of the pediatric studies.</p><p style="text-align:justify">There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.</p><p style="text-align:justify"><u>Neuroleptic Malignant Syndrome (NMS)</u><br />A potential fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs including brexpiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic drugs including brexpiprazole must be discontinued. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered.</p><p style="text-align:justify"><u>Tardive Dyskinesia</u><br />A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.</p><p style="text-align:justify">If signs and symptoms of tardive dyskinesia appear in a patient on brexpiprazole, dose reduction or discontinuation should be considered. These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</p><p style="text-align:justify">The risk of tardive dyskinesia and the likelihood that it will become irreversible increase with the duration of treatment and the cumulative dose. The syndrome can develop after a relatively brief&nbsp;treatment period, even at low doses. It may also occur after discontinuation of treatment.</p><p style="text-align:justify">There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, possibly masking the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p><p style="text-align:justify">Given these considerations, REXULTI should be prescribed in a manner most likely to reduce the risk of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients: (1) who suffer from a chronic illness that is known to respond to antipsychotic drugs; and (2) for whom alternative, effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, use the lowest dose and the shortest duration of treatment needed to produce a satisfactory clinical response. Periodically reassess the need for continued treatment.</p><p style="text-align:justify">If signs and symptoms of tardive dyskinesia appear in a patient on REXULTI, drug discontinuation should be considered. However, some patients may require treatment with REXULTI despite the presence of the syndrome.</p><p style="text-align:justify"><u>Metabolic Parameters</u><br />Atypical antipsychotic drugs, including REXULTI, have caused metabolic changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and body weight gain. Although all of the drugs in the class to date have been shown to produce some metabolic changes, each drug has its own specific risk profile.</p><p style="text-align:justify"><em>Hyperglycemia and Diabetes Mellitus:</em><br />Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication, and monitor periodically during long-term treatment. Patients treated with any antipsychotic agents should be observed for signs and symptoms of hyperglycemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus (e.g. obesity, family history of diabetes) should be monitored regularly for worsening of glucose control.</p><p style="text-align:justify"><u>Major Depressive Disorder</u><br />In the 6-week, placebo-controlled, fixed-dose clinical trials in patients with MDD, the proportions of patients with shifts in fasting glucose from normal (&lt;100 mg/dL) to high (&ge;126 mg/dL) and borderline (&ge;100 and &lt;126 mg/dL) to high were similar in patients treated with REXULTI and placebo.</p><p style="text-align:justify">In the long-term, open-label depression studies, 5% of patients with normal baseline fasting glucose experienced a shift to high while taking REXULTI+Antidepressant (ADT); 25% of subjects with borderline fasting glucose experienced shifts to high. Combined, 9% of subjects with normal or borderline fasting glucose experienced shifts to high fasting glucose during the long-term depression studies.</p><p style="text-align:justify"><u>Schizophrenia</u><br />In the 6-week, placebo-controlled, fixed-dose clinical trials in patients with schizophrenia, the proportions of patients with shifts in fasting glucose from normal (&lt;100 mg/dL) to high (&ge;126 mg/dL) or borderline (&ge;100 and &lt;126 mg/dL) to high were similar in patients treated with REXULTI and placebo.</p><p style="text-align:justify">In the long-term, open-label schizophrenia studies, 8% of patients with normal baseline fasting glucose experienced a shift from normal to high while taking REXULTI, 17% of subjects with borderline fasting glucose experienced shifts from borderline to high. Combined, 10% of subjects with normal or borderline fasting glucose experienced shifts to high fasting glucose during the long-term schizophrenia studies.</p><p style="text-align:justify"><em>Weight Gain and Dyslipidemia:</em><br />Antipsychotic drugs have been associated with metabolic changes, including weight gain and dyslipidemia. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment. Clinical monitoring of weight is recommended.</p><p style="text-align:justify"><u>Major Depressive Disorder</u><br />In the 6-week, placebo-controlled, fixed-dose clinical trials in patients with MDD, changes in fasting total cholesterol, LDL cholesterol, and HDL cholesterol were similar in REXULTI- and placebo-treated patients.</p><p style="text-align:justify"><u>Leukopenia, Neutropenia and Agranulocytosis</u><br />Leukopenia and neutropenia have been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in this class.</p><p style="text-align:justify">Possible risk factors for leukopenia and neutropenia include pre-existing low white blood cell count (WBC) or absolute neutrophil count (ANC) and history of drug-induced leukopenia or neutropenia. In patients with a pre-existing low WBC or ANC or a history of drug-induced leukopenia or neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of REXULTI at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p><p style="text-align:justify">Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue REXULTI in patients with absolute neutrophil count &lt;1000/mm3 and follow their WBC until recovery.</p><p style="text-align:justify"><u>Orthostatic Hypotension and Syncope</u><br />Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. In the short-term, placebo-controlled clinical studies of REXULTI+ADT in patients with MDD, the incidence of orthostatic hypotension-related adverse reactions in REXULTI+ADT-treated patients compared to placebo+ADT patients included: dizziness (2% vs. 2%) and orthostatic hypotension (0.1% vs. 0%). In the short-term, placebo-controlled clinical studies of REXULTI in patients with schizophrenia, the incidence of orthostatic hypotension-related adverse reactions in REXULTI-treated patients compared to placebo patients included: dizziness (2% versus 2%), orthostatic hypotension (0.4% versus 0.2%), and syncope (0.1% versus 0%).</p><p style="text-align:justify">Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension, (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients with<br />cerebrovascular disease. REXULTI has not been evaluated in patients with a recent history of myocardial infarction or unstable cardiovascular disease. Such patients were excluded from premarketing clinical trials.</p><p style="text-align:justify">Fall Antipsychotics, including REXULTI, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.</p><p style="text-align:justify"><u>Seizures</u><br />As with other antipsychotic drugs, Brexpiprazole should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.</p><p style="text-align:justify"><u>Body Temperature Regulation</u><br />Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing brexpiprazole for patients who will be experiencing conditions that may contribute to an elevation in core body temperature e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.</p><p style="text-align:justify"><u>Dysphagia</u><br />Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer&rsquo;s dementia. Brexpiprazole and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.</p><p style="text-align:justify"><u>Impulse-Control Disorders/Compulsive Behaviours</u><br />Post-marketing reports of impulse-control disorders including gambling have been reported very rarely in patients treated with brexpiprazole and other antipsychotics with partial agonist activity at dopamine receptors. Patients with a prior history of impulse-control disorders may be at increased risk and should be monitored carefully. Because patients may not recognize these behaviours as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased impulse-control disorders or other compulsive behaviours while being treated with brexpiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder. Compulsive behaviours may result in harm to the patient and others if not recognized. Consider dose reduction or stopping the medication if a patient develops such urges.</p><p style="text-align:justify"><u>Special Population</u><br /><em>Hepatic Impairment:</em><br />Patients with moderate to severe hepatic impairment (Child-Pugh score &ge;7) generally had higher exposure to brexpiprazole than patients with normal hepatic function; therefore, the maximum dose is reduced. In patients with varying degrees of hepatic impairment (Child-Pugh Classes A, B, and C), the AUC of oral brexpiprazole (2 mg single dose), compared to matched healthy subjects, increased 24% in mild hepatic impairment, increased 60% in moderate hepatic impairment, and did not change in severe hepatic impairment.</p><p style="text-align:justify"><em>Renal Impairment:</em><br />Patients with impaired renal function (CLcr&lt;60 mL/minute) had higher exposure to brexpiprazole than patients with normal renal function; therefore, the maximum dose is reduced. In patients with severe renal impairment (CLcr &lt;30 mL/min), AUC of oral brexpiprazole (2 mg single dose) compared to matched healthy subjects was increased by 68% while its Cmax was not changed.</p><p style="text-align:justify"><u>Paediatric Use</u><br />Safety and effectiveness in patients under the age of 18 years has not yet been systemically evaluated.</p><p style="text-align:justify"><u>Geriatric Use</u><br />Clinical studies of brexpiprazole did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p style="text-align:justify">Based on the results of a safety, tolerability and pharmacokineticspharmacokinetics (PK) trial, once daily oral administration of brexpiprazole (up to 3 mg/day for 14 days) as an adjunct therapy in the treatment of elderly subjects (70 to 85 years old, N=11) with MDD were comparable to that of the adult subjects with MDD.</p><p style="text-align:justify">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo.</p><p style="text-align:justify"><u>Other Special Populations</u><br />No dosage adjustment for brexpiprazole is required on the basis of a patient&rsquo;s sex, race, or smoking status</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Brexpiprazole is predominantly metabolized by CYP3A4 and CYP2D6. Based on results of drug interaction trials, dosing should be adjusted to half the recommended dose for patients administered with strong CYP2D6 or CYP3A4 inhibitors. Based on estimations from the population PK analysis, CYP2D6 EMs receiving both CYP3A4 and CYP2D6 inhibitors or CYP2D6 PMs receiving strong CYP3A4 inhibitors are expected to have approximately 4-5 fold increase in brexpiprazole concentrations; subsequently brexpiprazole dose should be accompanied with reduction of its dose to &frac14; of the recommended dosage in these situations [see 4.2 Dosing Precautions].</p><p style="text-align:justify">If brexpiprazole is used concomitantly with a strong CYP3A4 inducer (i.e. rifampicin), it is necessary to increase the dose by two fold and further adjust it based on clinical response [see4.2 Dosing Precautions].</p><p style="text-align:justify"><u>Medicinal Products</u><br /><em>Quinidine and Other Strong CYP2D6 Inhibitors:</em><br />Co-administration of a 2 mg single oral dose of brexpiprazole with quinidine (324 mg/day for 7 days), a potent inhibitor of CYP2D6, increased the AUC of brexpiprazole by 94%.</p><p style="text-align:justify"><em>Ketoconazole and Other Strong CYP3A4 Inhibitors:</em><br />Co-administration of ketoconazole (200 mg twice daily for 7 days), a potent inhibitor of CYP3A4, with a 2 mg single oral dose of brexpiprazole increased the AUC of brexpiprazole by 97%.</p><p style="text-align:justify"><em>Ticlopidine and Other CYP2B6 Inhibitors:</em><br />Co-administration of a 2 mg single oral dose of brexpiprazole with ticlopidine (250 mg twice daily for 7 days), a potent inhibitor of CYP2B6, had no effect on brexpiprazole.</p><p style="text-align:justify"><em>Rifampicin and Other CYP3A4 Inducers:</em><br />Co-administration of rifampin (600 mg twice daily for 12 days), a potent CYP3A4 inducer, with a single 4 mg oral dose of brexpiprazole resulted in an approximate 31% and 73% decrease in brexpiprazole Cmax and AUC.</p><p style="text-align:justify"><em>Gastric Acid pH Modifiers:</em><br />Co-administration of omeprazole (40 mg once daily, 5 days), a widely used proton pump inhibitor (PPI), with a single oral dose of brexpiprazole (4 mg) resulted in no effect on absorption of brexpiprazole. Other gastric acid pH modifiers (PPIs, H2 receptor antagonists, etc.) are also not expected to affect the absorption of brexpiprazole.</p><p style="text-align:justify"><em>Potential for brexpiprazole to Affect Other Drugs:</em><br />Based on results of in vitro studies, brexpiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. Clinical studies show that oral brexpiprazole (2 mg/day, 11 days) had no effect on the metabolism of dextromethorphan (a CYP2D6 substrate), lovastatin (a CYP3A4 substrate) or bupropion (a CYP2B6 substrate). Brexpiprazole does not affect absorption of drugs that are substrates of BCRP transporter (rosuvastatin) and PgP transporter (fexofenadine).</p><p style="text-align:justify"><u>Food</u><br />Intake of food has no effect on the pharmacokinetics of brexpiprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Safe use of brexpiprazole during pregnancy or lactation has not been established; therefore, use of brexpiprazole in pregnancy, in nursing mothers, or in women of childbearing potential requires that the benefits of treatment be weighed against the possible risks to mother and child.</p><p style="text-align:justify">Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been selflimited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p><p style="text-align:justify">The effect of brexpiprazole on labor and delivery in humans is unknown. Parturition in rats was not affected by brexpiprazole.</p><p style="text-align:justify">Brexpiprazole was excreted in milk of rats during lactation. It is not known whether brexpiprazole or its metabolites are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug considering the risk of drug discontinuation to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">REXULTI, like other antipsychotics, has the potential to impair judgment, thinking, or motor skills. In 6-week, placebo-controlled clinical trials in patients with MDD, somnolence (including sedation and hypersomnia) was reported in 4% for REXULTI+ADT-treated patients compared to 1% of placebo+ADT patients.</p><p style="text-align:justify">In 6-week, placebo-controlled clinical trials in patients with schizophrenia, somnolence (including sedation and hypersomnia) was reported in 5% of REXULTI-treated patients compared to 3% of placebotreated patients.</p><p style="text-align:justify">Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that REXULTI therapy does not affect them adversely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>MDD:</strong><br /><u>Summary of the safety profile</u><br />The most frequently observed adverse drug reactions (ADRs) reported in double-blind placebo controlled phase 2/3 clinical trials within the recommended doses (1-3 mg/day) were akathisia (9%), and weight gain (8%). Adverse reactions were usually mild or moderate and did not generally lead to cessation of therapy.</p><p style="text-align:justify"><u>Tabulated list of adverse reactions</u><br />The incidences of the ADRs associated with brexpiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials.</p><p style="text-align:justify">All ADRs are listed by system organ class and frequency: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="text-align:justify"><strong>System Organ Class</strong></td><td style="text-align:justify"><strong>Common<br />(&ge; 1% and &lt; 10%)</strong></td><td style="text-align:justify"><strong>Uncommon<br />(&ge; 0.1% and &lt; 1%)</strong></td></tr><tr><td style="text-align:justify">Metabolism and nutrition disorders</td><td style="text-align:justify">Increased appetite</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Psychiatric disorders</td><td style="text-align:justify">Restlessness, Insomnia Aniety</td><td style="text-align:justify">Tenion</td></tr><tr><td style="text-align:justify">Nervous system disorders</td><td style="text-align:justify">Akathisia, Tremor, Extrapyramidal disorder, Dizziness, Somnolence</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Eye disorders</td><td style="text-align:justify">Vision blurred</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Ear and labyrinth disorders</td><td style="text-align:justify">&nbsp;</td><td style="text-align:justify">Tinnitus</td></tr><tr><td style="text-align:justify">Cardiac disorders</td><td style="text-align:justify">&nbsp;</td><td style="text-align:justify">Palpitations</td></tr><tr><td style="text-align:justify">Vascular disorders</td><td style="text-align:justify">Hypertension</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Gastrointestinal disorders</td><td style="text-align:justify">Dry mouth, Abdominal pain, Constipation</td><td style="text-align:justify">Salivary hypersecretion</td></tr><tr><td style="text-align:justify">Skin and subcutaneous tissue<br />disorders</td><td style="text-align:justify">Rash</td><td style="text-align:justify">Night sweats</td></tr><tr><td style="text-align:justify">Musculoskeletal and connective<br />tissue disorders</td><td style="text-align:justify">Back pain</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">General disorders and<br />administration site conditions</td><td style="text-align:justify">Fatigue</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Investigations</td><td style="text-align:justify">Weight increased, Blood prolactin increased, Blood cortisol decreased,</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Injury, poisoning and procedural complications</td><td style="text-align:justify">Muscle strain</td><td style="text-align:justify">&nbsp;</td></tr></tbody></table><p style="text-align:justify">Additional adverse drug reactions were reported: dyspepsia , agitation, and hypersensitivity.</p><p style="text-align:justify"><u>Description of selected adverse reactions</u><br /><em>EPS related events:</em><br />In short-term placebo controlled trials, the incidence of EPS-related events, excluding akathisia events, was 7.7% for brexpiprazole-treated subjects versus 4.6% for placebo-treated subjects.</p><p style="text-align:justify">The incidence of akathisia for brexpiprazole-treated subjects was 9.2% versus 2.8% for placebo-treated subjects. New occurrences of akathisia were reported in all treatment arms more often within the first weeks following treatment initiation and they were mild to moderate in severity.</p><p style="text-align:justify"><em>Weight Gain</em><br />The percentage of subjects in short-term placebo-controlled trials who had a potentially clinically relevant increase in body weight (7%) was 4.7 % for brexpiprazole compared with 1.5 % in the placebo group. The mean body weight increase in the short-term trials at last visit was 1.5 kg for brexpiprazole compared with 0.3 kg in the placebo group.</p><p style="text-align:justify">In the long-term, open-label schizophrenia studies, the mean change in body weight from baseline to last visit was 2.7 kg at last observation.</p><p style="text-align:justify"><strong>Schizophrenia</strong><br /><u>Summary of the safety profile</u><br />The most frequently observed adverse drug reactions (ADRs) reported in double-blind placebo controlled phase 2/ 3 clinical trials within the recommended doses (2-4 mg/day) were akathisia (6%), and weight gain (5%). Adverse reactions were usually mild or moderate and did not generally lead to cessation of therapy.</p><p style="text-align:justify"><u>Tabulated list of adverse reactions</u><br />The incidences of the ADRs associated with brexpiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials.</p><p style="text-align:justify">All ADRs are listed by system organ class and frequency: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="text-align:justify"><strong>System Organ Class</strong></td><td style="text-align:justify"><strong>Common<br />(&ge; 1% and &lt; 10%)</strong></td><td style="text-align:justify"><strong>Uncommon<br />(&ge; 0.1% and &lt; 1%)</strong></td></tr><tr><td style="text-align:justify">Psychiatric disorders</td><td style="text-align:justify">Restlessness</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Nervous system disorders</td><td style="text-align:justify">Akathisia, Tremor, Extrapyramidal disorder, Dizziness, Somnolence</td><td style="text-align:justify">Parkinsonism</td></tr><tr><td style="text-align:justify">Respiratory, thoracic and mediastinal disorders</td><td style="text-align:justify">&nbsp;</td><td style="text-align:justify">Cough</td></tr><tr><td style="text-align:justify">Gastrointestinal disorders</td><td style="text-align:justify">Dry mouth, Abdominal pain, Diarrheoa</td><td style="text-align:justify">Flatulence</td></tr><tr><td style="text-align:justify">Skin and subcutaneous tissue<br />disorders</td><td style="text-align:justify">Rash</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Musculoskeletal and connective<br />tissue disorders</td><td style="text-align:justify">Back pain,&nbsp;Pain in extremity</td><td style="text-align:justify">Myalgia</td></tr><tr><td style="text-align:justify">General disorders and<br />administration site conditions</td><td style="text-align:justify">Pain</td><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">Investigations</td><td style="text-align:justify">Weight increased, Creatinine Phosphokinase Increased</td><td><p style="text-align:justify">&nbsp;</p></td></tr></tbody></table><p style="text-align:justify">Additional adverse drug reactions were reported: constipation, dyspepsia, fatigue, increased appetite, somnolence, agitation, anxiety, insomnia, hypersensitivity and blood prolactin increased .</p><p style="text-align:justify"><u>Description of selected adverse reactions</u><br /><em>Akathisia and EPS related ADRs</em><br />In short-term placebo controlled trials, the incidence of EPS-related events, excluding akathisia events, was 7.1% for brexpiprazole-treated subjects versus 5.6 % for placebo-treated subjects. The incidence of akathisia events for brexpiprazole treated subjects was 5.8% versus 4.0% for placebo-treated subjects.</p><p style="text-align:justify">New occurrences of akathisia were reported in all treatment arms more often within the first weeks following treatment initiation and they were mild to moderate in severity.</p><p style="text-align:justify"><em>Weight Gain</em><br />The percentage of subjects in short-term placebo-controlled trials who had a potentially clinically relevant increase in body weight (7%) was 10.3 % for brexpiprazole compared with 4.4 % in the placebo group. The mean body weight increase in the short-term trials at last visit was 1.2 kg for brexpiprazole compared with 0.2 kg in the placebo group. (In the long-term, open-label schizophrenia studies, the mean change in body weight from baseline to last visit was 1.1 kg at last observation.</p><p style="text-align:justify"><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p style="text-align:justify">To report any side effect(s):</p><ul><li style="text-align: justify;"><strong>Saudi Arabia:</strong><ul><li>The National Pharmacovigilance Centre (NPC)<ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa&nbsp;</li></ul></li></ul></li><li style="text-align: justify;"><strong>Other GCC States:</strong><br />Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No specific information is available on the treatment of overdose with brexpiprazole. Gastric lavage and treatment with an emetic may be useful immediately after overdose. An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.</p><p style="text-align:justify">Consult a certified POISON CONTROL CENTER for up to date guidance and advice.<br />Oral activated charcoal and sorbitol (50 g/240 mL), administered one hour after ingesting oral brexpiprazole, decreased brexpiprazole Cmax and AUC by approximately 5% to 23% and 31% to 39% respectively; however, there is insufficient information available on the therapeutic potential of activated charcoal in treating an overdose with brexpiprazole. Although there is no information on the effect of haemodialysis in treating an overdose with brexpiprazole, haemodialysis is unlikely to be useful in overdose management since brexpiprazole is highly bound to plasma proteins.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Brexpiprazole has high affinity (Ki&lt;5 nM) for multiple monoaminergic receptors including serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT7, dopamine D2, D3, and noradrenergic &alpha;1A, &alpha;1B, &alpha;1D, and &alpha;2C receptors. Brexpiprazole acts as a partial agonist at the 5-HT1A, D2, and D3 receptors and as an antagonist at 5-HT2A, 5-HT2B, 5-HT7, &alpha;1A, &alpha;1B, &alpha;1D, and &alpha;2C receptors. Brexpiprazole exhibits a moderate affinity for histamine H1 receptor (19 nM) and a very weak affinity for muscarinic M1 receptor (67% inhibition at 10 &mu;M). Dose-response occupancy and brain/plasma exposure relationship were determined in vivo or ex vivo for D2/D3, 5-HT2A, 5-HT1A, 5-HT6, and 5-HT7 receptors as well as for the 5-HT transporter in preclinical studies. These results are consistent with the relative in vitro binding affinities and indicate that brexpiprazole has potent activity at several targets in the central nervous system (CNS) at relevant plasma exposures.</p><p style="text-align:justify">Despite a low intrinsic activity at the D2 receptor and potent antipsychotic effect, brexpiprazole showed low liability for catalepsy (animal model for extrapyramidal side effect) and for inducing tardive dyskinesia (indicative of post-synaptic D2 receptors increased sensitivity). The potencies of these effects were similar or lower to other antipsychotic agents. Brexpiprazole showed very low tendency to induce ptosis(animal model for sedation) and its relatively low binding affinity to H1 receptor compared to that for D2 receptor would further suggest a low potential for H1-related sedative effect.</p><p style="text-align:justify">Brexpiprazole does not prolong QTcI or QTcF at the clinical (4 mg) or at a supra-therapeutic (12 mg) dose range, and no correlation has been observed between brexpiprazole concentrations and QTcI or QTcF prolongation. No apparent dose dependent categorical changes in QTc and brexpiprazole dose was observed.</p><p style="text-align:justify"><u>Mechanism of Action</u><br />Brexpiprazole binds with high affinity to multiple serotonin, dopamine and noradrenergic receptors. While the precise mechanism of action of brexpiprazole in treating psychiatric conditions is unknown, the pharmacology of brexpiprazole is believed to be mediated by a combination of high binding affinity and functional activities at multiple monoaminergic receptors. It has modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors, with similar high affinities at all of these receptors (Ki: 0.1-0.5 nM). Brexpiprazole also shows antagonist activity at noradrenergic &alpha;1B/2C with affinity in the same sub-nanomolar Ki range (Ki: 0.2-0.6 nM). The 5 HT1A/D2 receptor partial agonist activity in combination with 5&not;HT2A and &alpha;1B/2C receptors antagonism of brexpiprazole may contribute with antipsychotic efficacy.</p><p style="text-align:justify"><u>Clinical efficacy</u><br /><em>Major Depressive Disorder</em><br />The efficacy of brexpiprazole in the adjunctive treatment of major depressive disorder (MDD) was demonstrated in two 6-week, placebo-controlled, fixed-dose trials of adult patients meeting DSM-IV-TR criteria for MDD, with or without symptoms of anxiety, who had an inadequate response to prior antidepressant therapy (1 to 3 courses) in the current episode and who had also demonstrated an inadequate response throughout the 8 weeks of prospective antidepressant treatment (escitalopram, fluoxetine, paroxetine controlled-release, sertraline, duloxetine delayed release, or venlafaxine extended release). Inadequate response during the prospective antidepressant treatment phase was defined as having persistent symptoms without substantial improvement throughout the course of treatment.</p><p style="text-align:justify">The primary endpoint was change from baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-related scale used to assess the degree of depressive symptomatology (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts). The key secondary endpoint was the Sheehan Disability Scale (SDS), a 3-item self-rated instrument used to assess the impact of depression on three domains of functioning (work/school, social life, and family life) with each item scored from 0 (not at all) to 10 (extreme).</p><p style="text-align:justify">At randomization, the mean MADRS total score was 27. In the two 6-week, placebo controlled trials, brexpiprazole +ADT 2 mg/day and 3 mg/day demonstrated efficacy over placebo +ADT in reducing mean MADRS total scores. Brexpiprazole +ADT 2 mg/day and 3 mg/day also demonstrated efficacy over placebo +ADT in improving functioning as measured by the SDS mean score. Results from the primary and key secondary efficacy parameters for both fixed dose trials are shown below.</p><p style="text-align:justify">An examination of population subgroups did not reveal evidence of differential response based on age, gender, race or choice of prospective antidepressant.</p><p style="text-align:justify"><strong>Summary of Efficacy Results for Pivotal Studies in Adjunctive Treatment of MDD</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="text-align:justify">Stu<strong>dy</strong></td><td style="text-align:justify"><strong>Treatment Group</strong></td><td style="text-align:justify"><strong>N</strong></td><td style="text-align:justify"><strong>Mean Baseline Score (SD)</strong></td><td style="text-align:justify"><strong>I.S Mean Change from Baseline (SE)</strong></td><td style="text-align:justify"><strong>Placebo-subtracted Difference<sup>a</sup> (95% CI)</strong></td></tr><tr><td colspan="6" style="text-align:justify">Primary Efficacy Measure: MADRS</td></tr><tr><td rowspan="2" colspan="1" style="text-align:justify">1</td><td style="text-align:justify">brexpiprazole (2 mg/day) +ADT*</td><td style="text-align:justify">175</td><td style="text-align:justify">26.87 (5.71)</td><td style="text-align:justify">-8.36 (0.64)</td><td style="text-align:justify">-3.21&nbsp;(-4.87, -1.54)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">178</td><td style="text-align:justify">27.32 (5.64)</td><td style="text-align:justify">-5.15 (0.63)</td><td style="text-align:justify">-</td></tr><tr><td rowspan="2" colspan="1" style="text-align:justify">2</td><td style="text-align:justify">brexpiprazole (3 mg/day) +ADT*</td><td style="text-align:justify">213</td><td style="text-align:justify">26.48 (5.29</td><td style="text-align:justify">-8.29 (0.53)</td><td style="text-align:justify">-1.95 (-3.39, -0.51)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">203</td><td style="text-align:justify">26.46 (5.20)</td><td style="text-align:justify">-6.33 (0.53)</td><td style="text-align:justify">-</td></tr><tr><td colspan="6" style="text-align:justify">Key Secondary Efficacy Measure: SDS</td></tr><tr><td rowspan="2" colspan="1" style="text-align:justify">1</td><td style="text-align:justify">brexpiprazole (2 mg/day) +ADT*</td><td style="text-align:justify">167</td><td style="text-align:justify">6.03&nbsp;(1.94)</td><td style="text-align:justify">-1.35 (0.17)</td><td style="text-align:justify">-0.46 (-0.88, -0.03)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">170</td><td style="text-align:justify">6.34 (2.15)</td><td style="text-align:justify">-0.89 (0.17)</td><td style="text-align:justify">-</td></tr><tr><td rowspan="2" colspan="1" style="text-align:justify">2</td><td style="text-align:justify">brexpiprazole (3 mg/day) +ADT*</td><td style="text-align:justify">201</td><td style="text-align:justify">5.81 (2.25)</td><td style="text-align:justify">-1.26 (0.15)</td><td style="text-align:justify">-0.48 (-0.88, -0.08)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">194</td><td style="text-align:justify">5.62 (1.90)</td><td style="text-align:justify">-0.78 (0.15)</td><td style="text-align:justify">-</td></tr></tbody></table><p style="text-align:justify">SD=standard deviation; SE=standard error; LS Mean=least-squares mean; CI=unadjusted confidence interval<br />* Dose statistically significantly superior to placebo<br /><sup>a</sup> Difference (drug minus placebo) in least-squares mean change from baseline</p><p style="text-align:justify"><em>Schizophrenia</em><br />The efficacy of brexpiprazole in adults with schizophrenia was demonstrated in two 6-week, placebocontrolled, fixed-dose clinical trials in patients who met DSM-IV-TR criteria for schizophrenia.</p><p style="text-align:justify">The primary efficacy endpoint of both trials was change from baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) total score using MMRM analysis. The primary instrument for evaluating efficacy was the Positive and Negative Syndrome Scale, a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. PANSS total score may range from 30 (absent symptoms) to 210 (extreme).</p><p style="text-align:justify">The key secondary endpoint of both trials was change from baseline to Week 6 in Clinical Global Impression Severity of Illness Scale (CGI-S) total score, a validated clinician-related scale that measures the patient&rsquo;s current illness state and overall clinical state on a 1 (normal, not at all ill) to 7-point (extremely ill) scale.</p><p style="text-align:justify">In both trials, brexpiprazole 4 mg/day demonstrated efficacy over placebo in the PANSS total score and showed greater improvement in CGI-S score compared to placebo. In one trial, brexpiprazole 2 mg/day demonstrated efficacy over placebo in the PANSS total score and CGI-S score. Results from the primary and key secondary efficacy parameters for both fixed dose trials are shown below.</p><p style="text-align:justify">Examination of population subgroups based on age, gender and race did not show any statistical evidence of differential responsiveness</p><p style="text-align:justify"><strong>Summary of Efficacy Results for Pivotal Studies in Schizophrenia</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="text-align:justify"><strong>Study</strong></td><td style="text-align:justify"><strong>Treatment Group</strong></td><td style="text-align:justify"><strong>N</strong></td><td style="text-align:justify"><strong>Mean Baseline Score (SD)</strong></td><td style="text-align:justify"><strong>I.S Mean Change from Baseline (SE)</strong></td><td style="text-align:justify"><strong>Placebo-subtracted Difference<sup>a</sup> (95% CI)</strong></td></tr><tr><td colspan="6" style="text-align:justify">Primary Efficacy Measure: PANSS</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">1</td><td style="text-align:justify">brexpiprazole (2 mg/day) +ADT*</td><td style="text-align:justify">180</td><td style="text-align:justify">95.85 (13.75)</td><td style="text-align:justify">-20.73 (1.55)</td><td style="text-align:justify">-8.72 (-13.1, -4.37)</td></tr><tr><td style="text-align:justify">brexpiprazole (4 mg/day) +ADT*</td><td style="text-align:justify">178</td><td style="text-align:justify">94.70 (12.06)</td><td style="text-align:justify">-19.65 (1.54)</td><td style="text-align:justify">-7.64 (-12.0, -3.30)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">178</td><td style="text-align:justify">95.69 (11.46)</td><td style="text-align:justify">-12.01 (1.60)</td><td style="text-align:justify">-</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">2</td><td style="text-align:justify">brexpiprazole (2 mg/day) +ADT*</td><td style="text-align:justify">179</td><td style="text-align:justify">96.30 (12.91)</td><td style="text-align:justify">-16.61 (1.49)</td><td style="text-align:justify">-3.08 (-7.23, 1.07)</td></tr><tr><td style="text-align:justify">brexpiprazole (4 mg/day) +ADT*</td><td style="text-align:justify">181</td><td style="text-align:justify">94.99 (12.38)</td><td style="text-align:justify">-20.00 (1.48)</td><td style="text-align:justify">-6.47 (-10-6, -2.35)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">180</td><td style="text-align:justify">94.63 (12.84)</td><td style="text-align:justify">-13.53 (1.52)</td><td style="text-align:justify">-</td></tr><tr><td colspan="6" style="text-align:justify">Key Secondary Efficacy Measure: CGI-S</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">1</td><td style="text-align:justify">brexpiprazole (2 mg/day) +ADT*</td><td style="text-align:justify">181</td><td style="text-align:justify">4.90 (0.64)</td><td style="text-align:justify">-1.15 (0.08)</td><td style="text-align:justify">-0.33 (-0.56, -0.10)</td></tr><tr><td style="text-align:justify">brexpiprazole (4 mg/day) +ADT*</td><td style="text-align:justify">178</td><td style="text-align:justify">4.81 (0.64)</td><td style="text-align:justify">-1.20 (0.08)</td><td style="text-align:justify">-0.38 (-0.61, -0.15)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">181</td><td style="text-align:justify">4.84 (0.66)</td><td style="text-align:justify">-0.82 (0.09)</td><td style="text-align:justify">-</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">2</td><td style="text-align:justify">brexpiprazole (2 mg/day) +ADT*</td><td style="text-align:justify">180</td><td style="text-align:justify">4.96 (0.65)</td><td style="text-align:justify">-0.99 (0.09)</td><td style="text-align:justify">-0.19 (-0.42, 0.05)</td></tr><tr><td style="text-align:justify">brexpiprazole (4 mg/day) +ADT*</td><td style="text-align:justify">183</td><td style="text-align:justify">4.85 (0.64)<br />&nbsp;</td><td style="text-align:justify">-1.19 (0.08)<br />&nbsp;</td><td style="text-align:justify">-0.38 (-0.62, -0.15)</td></tr><tr><td style="text-align:justify">Placebo +ADT</td><td style="text-align:justify">181<br />&nbsp;</td><td style="text-align:justify">4.87 (0.61)</td><td style="text-align:justify">-0.81 (0.09)</td><td style="text-align:justify">-</td></tr></tbody></table><p style="text-align:justify">SD=standard deviation; SE=standard error; LS Mean=least-squares mean; CI=unadjusted confidence interval<br />* Dose statistically significantly superior to placebo<br /><sup>a</sup> Difference (drug minus placebo) in least-squares mean change from baseline</p><p style="text-align:justify"><em>Maintenance:</em><br />The safety and efficacy of brexpiprazole as maintenance treatment in adults with schizophrenia aged 18 to 65 years were demonstrated in a 52-week maintenance phase of a randomized withdrawal trial. A pre-specified interim analysis demonstrated a statistically significantly longer time to impending relapse in patients randomized to the brexpiprazole group (1 mg/day to 4 mg/day) compared to placebo-treated patients and the trial was subsequently terminated early because maintenance of efficacy had been demonstrated. The final analysis demonstrated a longer time to impending relapse in patients randomized to the brexpiprazole group compared to placebo-treated patients. The key secondary endpoint, the proportion of patients who met the criteria for impending relapse, was lower in brexpiprazole-treated patients (13.5%) compared with placebo group (38.5%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Absorption</u><br />Brexpiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 4.0 hours after single dose administrations; the absolute oral bioavailability of the tablet formulation is 95.1%. Brexpiprazole steady-state concentrations are attained within 10-12 days of dosing. Brexpiprazole can be administered with or without food. Administration of a 4 mg brexpiprazole tablet with a standard high fat meal did not significantly affect the Cmax or AUC of brexpiprazole.</p><p style="text-align:justify">After single and multiple once daily dose administration, brexpiprazole exposure (Cmax and AUC) increase in proportion to the dose administered. In vitro studies of brexpiprazole do not indicate that brexpiprazole is a substrate of efflux transporters such as MDRI (P-gp) and BCRP.</p><p style="text-align:justify"><u>Distribution</u><br />The volume of distribution of brexpiprazole following intravenous administration is high (1.56&plusmn;0.418l/kg), indicating extravascular distribution. Brexpiprazole is highly protein bound in plasma (greater than 99%) to serum albumin and &alpha;1-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment. Based on results of in vitro studies brexpiprazole protein binding is not affected by warfarin, diazepam, and digitoxin.</p><p style="text-align:justify"><u>Metabolism and Elimination</u><br />Based on in vitro metabolism studies of brexpiprazole using recombinant human cytochrome P450 (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4), the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6. The in vitro inhibitory potential of brexpiprazole on MDR1 (P-gp), OAT1, OAT3, OCT2, multidrug and toxin extruders (MATE1), MATE2-K, OATP1B1, OATP1B3, and OCT1 has also been evaluated; brexpiprazole was only identified as a potential inhibitor of the BCRP efflux transporter but was not considered to be an inhibitor for the other tested transporters.</p><p style="text-align:justify"><em>In vivo</em> brexpiprazole is metabolized primarily by CYP3A4 and CYP2D6 enzymes. After single and multiple dose administrations, brexpiprazole and a major metabolite, DM 3411, are the predominant drug moieties in the systemic circulation. At steady-state, DM-3411 represents 23.1-47.7% of brexpiprazole exposure (AUC) in plasma. It should be noted that in vivo preclinical studies have shown that at clinically relevant plasma exposures of brexpiprazole, DM-3411 brain exposures were below the detection limit. Thus, DM-3411 is considered not to contribute to the therapeutic effects of brexpiprazole.</p><p style="text-align:justify">Based on the results of in vitro data, brexpiprazole showed little to no inhibition of CYP450 isozymes.</p><p style="text-align:justify">Following a single oral dose of [14 C]-labeled brexpiprazole, approximately 24.6% and 46% of the administered radioactivity was recovered in the urine and feces, respectively. Less than 1% of unchanged brexpiprazole was excreted in the urine and approximately 14% of the oral dose was recovered unchanged in the feces. Apparent oral clearance of brexpiprazole oral tablet after once daily administration is 19.8 (&plusmn;11.4) mL/h/kg. After multiple once daily administration of brexpiprazole, the terminal elimination half-life of brexpiprazole and its major metabolite, DM-3411, is 91.4 hours and 85.7 hours, respectively.</p><p style="text-align:justify"><u>Special Populations</u><br /><em>Age/Gender:</em><br />After single dose administration of brexpiprazole (2 mg), elderly subjects (older than 65 years old) exhibited similar brexpiprazole systemic exposure (Cmax and AUC) in comparison with the adult subjects (18-45 years old) and female subjects exhibited approximately 40-50% higher brexpiprazole systemic exposure (Cmax and AUC) in comparison to the male subjects. Population pharmacokinetic evaluation identified age and female sex as statistically significant covariates affecting brexpiprazole PK and not considered clinically relevant.</p><p style="text-align:justify"><em>Race</em>:<br />Although no specific pharmacokinetic study was conducted to investigate the effects of race on the disposition of brexpiprazole, population pharmacokinetic evaluation revealed no evidence of clinically significant race-related differences in the pharmacokinetics of brexpiprazole.</p><p style="text-align:justify"><em>CYP2D6 Poor Metabolisers:</em><br />Approximately 8% of whites and 3&ndash;8% of black people lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). Population pharmacokinetic evaluation shows that CYP2D6 PMs have 47% higher exposure to brexpiprazole compared to EMs.</p><p style="text-align:justify"><em>Smoking</em>:<br />Based on studies utilizing human liver enzymes in vitro, brexpiprazole is not a substrate for CYP1A2. Smoking should, therefore, not have an effect on the pharmacokinetics of brexpiprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Abuse/liability</u><br />Brexpiprazole showed neither a potential to produce physical dependence in rats nor a reinforcing effect in rhesus monkeys. In a drug abuse liability study in rats, no withdrawal signs suggestive of physical dependence were evident. Brexpiprazole is not considered to have potential to produce physical dependence.</p><p style="text-align:justify"><u>Carcinogenicity, and mutagenesis</u><br />The lifetime carcinogenic potential of brexpiprazole was evaluated in a two year study in ICR mice and Sprague-Dawley rats. Brexpiprazole was administered orally (gavage) for two years to mice at doses of 0.75, 2 and 5 mg/kg/day (0.9 to 6.1-fold the 4 mg oral maximum recommended human dose [MRHD] for a 60 kg patient based on body surface area).There was no increase in the incidence of tumors in males at any dose group. In female mice, there was an increased incidence of mammary gland adenocarcinoma and adenosquamous carcinoma, and pars distalis adenoma of the pituitary gland. Brexpiprazole was administered orally (gavage) for two years to rats at doses of 1, 3 and 10 mg/kg/day in male rats or 3, 10 and 30 mg/kg/day in female rats (for males 2.4 to 24.3-fold and for females 7.3 to 72.9-fold the 4 mg oral MRHD for a 60 kg patient based on body surface area). Long-term administration of brexpiprazole to rats did not induce neoplastic lesions.</p><p style="text-align:justify">Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin mediated. The potential for increasing serum prolactin level of brexpiprazole was shown in both mice and rats. The relevance for human risk of the findings of prolactin- mediated endocrine tumors in rodents is unknown.</p><p style="text-align:justify">The mutagenic potential of brexpiprazole was tested in the in vitro bacterial reverse mutation assay, the in vitro forward gene mutation assay in mouse lymphoma cells, the in vitro chromosomal aberration assay in Chinese hamster ovary (CHO) cells, the in vivo micronucleus assay in rats, and the unscheduled DNA synthesis assay in rats. In vitro with mammalian cells brexpiprazole was mutagenic and clastogenic but occurred at doses that induced cytotoxicity. No mutagenicity or genotoxicity was observed in other studies. Based on a weight of evidence, brexpiprazole is not considered to present a genotoxic risk to humans at therapeutic doses and exposures.</p><p style="text-align:justify"><u>Teratogenic effects</u><br />Brexpiprazole was not teratogenic and did not cause adverse developmental effects in developmental toxicity studies in which pregnant rats and rabbits were given brexpiprazole during the period of organogenesis at doses up to 30 mg/kg/day (73-fold and 146-fold for rats and rabbits, respectively of the 4 mg/day oral MRHD for a 60 kg patient based on body surface area).</p><p style="text-align:justify">In a rabbit embryo-fetal development study (at 150 mg/kg/day, a dose that induced maternal toxicity), decreased body weight, retarded ossification, and increased incidences of visceral and skeletal variations were observed in fetuses.</p><p style="text-align:justify"><u>Impairment of Fertility</u><br />Female rats were treated with oral doses of 0.3, 3 or 30 mg/kg/day (0.7, 7.3, and 73 times the oral MRHD on a mg/m2 basis) prior to mating with untreated males and continuing through conception and implantation. Estrus cycle irregularities and decreased fertility were observed at 3 and 30 mg/kg/day. Prolonged duration of pairing and increased preimplantation losses were observed at 30 mg/kg/day.</p><p style="text-align:justify">Male rats were treated with oral doses of 3, 10, or 100 mg/kg/day (7.3, 24 and 240 times the oral MRHD on a mg/m2 basis) for 63 days prior to mating with untreated females and throughout the 14 days of mating. No differences were observed in the duration of mating or fertility indices in males at any dose of brexpiprazole.</p><p style="text-align:justify"><u>Cardiovascular Toxicity</u><br />Decreased blood pressure and prolonged QT interval and QTc were noted in the conscious dog in the safety pharmacology study of the 13-week repeat-dose toxicity study with monkeys and in the juvenile toxicity study with dogs. The effect of brexpiprazole on decreased blood pressure was suggested to be due to a blockade of &alpha;1- adrenoceptors in peripheral blood vessels, which is consistent with the pharmacological profile for this compound.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The active substance is brexpiprazole. Each tablet contains 0.25 mg/ 0.5 mg / 1 mg / 2 mg / 3 mg / 4mg of brexpiprazole respectively.</p><p>The other excipients are lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, titanium dioxide, iron oxide red (0.25 mg, 0.5 mg, 3 mg), iron oxide yellow (0.25 mg, 0.5 mg, 1 mg, 2 mg), ferrosoferric oxide (0.25 mg, 2 mg, 3mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above&nbsp;30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><strong>Strenght</strong></td><td><strong>Shape</strong></td><td><strong>Color</strong></td><td><strong>Marking</strong></td></tr><tr><td>0.25mg</td><td>Round, shallow<br />convex and beveledged</td><td>light brown</td><td>debossed with BRX<br />and 0.25 one side</td></tr><tr><td>0.5mg</td><td>Round, shallow<br />convex and beveledged</td><td>light orange</td><td>debossed with BRX<br />and 0.5 one side</td></tr><tr><td>1mg</td><td>Round, shallow<br />convex and beveledged</td><td>light yellow</td><td>debossed with BRX<br />and 1 one side</td></tr><tr><td>2mg</td><td>Round, shallow<br />convex and beveledged</td><td>light green</td><td>debossed with BRX<br />and 2 one side</td></tr><tr><td>3mg</td><td>Round, shallow<br />convex and beveledged</td><td>light purple</td><td>debossed with BRX<br />and 3 one side</td></tr><tr><td>4mg</td><td>Round, shallow<br />convex and beveledged</td><td>white</td><td>debossed with BRX<br />and 4 one side</td></tr></tbody></table><p>Brexpiprazole tablets are supplied in blisters packed in cartons containing 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900
Manufacturer
Elaiapharm
2881 Route des Crêtes,
Z.I. Les Bouillides Sophia Antipolis,
06560 Valbonne
France
H. Lundbeck A/S
Ottiliavej 9
2500 Valby
Denmark
Under License from Otsuka Pharmaceutical Co., Ltd
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>